Delivery Order SPE2DB24D2101-SPE2DB25FKNTW
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,136.53 for RINVOQ ER 15 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,605.35 on August 20, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of RINVOQ ER 15 mg tablets in a quantity of 30 units. This firm fixed-price delivery order, valued at $3,819.30, represents a competitive award with no set-aside designation and carries an ultimate completion date of July 28, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $11,431.86 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 28, 2025, with completion scheduled for August 29, 2025. This firm fixed-price, non-set-aside delivery order represents a single pharmaceutical procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $101,921.94 by the Defense Logistics Agency on August 12, 2025, with an ultimate completion date of August 13, 2025. The contract, awarded under firm fixed price terms with no set-aside designation, covers the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This delivery order is a child contract under AmerisourceBergen's significant...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,223.32 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages) on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed price delivery order represents a non-competitive, non-set-aside procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $6,657.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $6,223.32 for RINVOQ ER 30 mg tablets (30-count units) under a firm fixed price contract type. The award was issued on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside competitive award, reflecting AmerisourceBergen's capability to meet...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $7,492.61 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of RINVOQ ER 15 MG TABLET pharmaceutical products. The contract has a performance period through March 12, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is part of a larger indefinite delivery contract (IDC) the company holds with DLA Troop Support Medical...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKNTWDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,326.30 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count unit dose packaging) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price delivery order represents a direct fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and primary distribution center. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. As the prime contractor on this delivery order, the company supplies a broad portfolio of pharmaceutical products across multiple therapeutic domains to federal customers including the Defense Health Agency and U.S. Coast Guard. This award reflects AmerisourceBergen's established capability to meet competitive federal procurement requirements and its role in the DLA's pharmaceutical procurement strategy, which is transitioning toward a Pharmaceutical Prime Vendor Global Program Generation V model with multiple regional contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 8/22/25 |